Lucentis® using visudyne® study: Determining the threshold-dose fluence of verteporfin photodynamic therapy combined with intravitreal ranibizumab for exudative macular degeneration

Eric Chen, David M. Brown, Tien P. Wong, Matthew S. Benz, Eric Kegley, Joel Cox, Richard H. Fish, Rosa Y. Kim

Research output: Contribution to journalArticle

21 Scopus citations

Abstract

Purpose: Combination verteporfin photodynamic therapy (vPDT) and antivascular endothelial growth factor (anti-VEGF) therapy may decrease the need for injections while maintaining visual acuity in exudative age-related macular degeneration. This pilot study was designed to determine the threshold fluence dose of vPDT (the dose required to demonstrate an effect on choroidal perfusion) combined with ranibizumab. Methods: Seven patients were randomized to sham vPDT (two patients), 20% fluence vPDT (two patients), or 40% fluence vPDT (three patients) in combination with three-monthly intravitreal 0.5 mg ranibizumab injections. Intravitreal ranibizumab was reinjected if disease activity was seen on fluorescein angiography, optical coherence tomography, or clinical examination. Indocyanine green-determined choroidal hypoperfusion was graded in a masked fashion. Results: Patients with 20% vPDT had mild hypoperfusion defects at seven days that resolved by week 4 (threshold dose); patients with 40% fluence vPDT had marked hypoperfusion at seven days that persisted as long as 12 months. Recruitment was stopped after limited efficacy was observed. One patient with 20% fluence vPDT lost 19 letters at one year; no other patient lost or gained > 10 letters. Central retinal thickness decreased in six of seven patients, but ranibizumab injections did not decrease. Conclusion: This pilot study shows that the threshold fluence dose of vPDT (when combined with ranibizumab) is approximately 20% standard fluence, and that mild and transient choroidal hypoperfusion can occur. Forty percent fluence vPDT causes a more prolonged and striking hypoperfusion. Despite hypoperfusion, no decrease in visual acuity or injections required was noted, suggesting that even higher fluence levels of vPDT may be necessary to decrease the number of anti-VEGF injections.

Original languageEnglish (US)
Pages (from-to)1073-1079
Number of pages7
JournalClinical Ophthalmology
Volume4
Issue number1
DOIs
StatePublished - 2010

Keywords

  • Choroidal hypoperfusion
  • Neovascular age-related macular degeneration
  • Threshold dose
  • Verteporfin photodynamic therapy

ASJC Scopus subject areas

  • Ophthalmology

Fingerprint Dive into the research topics of 'Lucentis® using visudyne® study: Determining the threshold-dose fluence of verteporfin photodynamic therapy combined with intravitreal ranibizumab for exudative macular degeneration'. Together they form a unique fingerprint.

Cite this